Raffaele Colombo/LinkedIn
Oct 4, 2024, 17:28
Raffaele Colombo: sBLA for T-DXd has been accepted by FDA HER2-low or HER2-ultralow breast cancer
Raffaele Colombo shared a post on X:
“sBLA for trastuzumab deruxtecan (T-DXd) has been accepted by FDA (and granted Priority Review) for patients with HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining < IHC 1+) breast cancer after at least one endocrine therapy, based on DESTINY-Breast06.”
Source: Raffaele Colombo/X
Raffaele Colombo, a leading figure in the pharmaceutical industry is the Associate Director of Medicinal Chemistry at Zymeworks Inc.. His leadership and scientific acumen drive the discovery and optimization of novel drug candidates and advancing the treatment landscape for various diseases.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 8, 2025, 17:21
Aug 8, 2025, 17:21
Aug 8, 2025, 16:46
Aug 8, 2025, 16:41
Aug 8, 2025, 16:31
Aug 8, 2025, 16:11
Aug 8, 2025, 15:57
Aug 8, 2025, 15:54